Published in Int J Cancer on October 21, 1997
Bench to bedside and back again: molecular mechanisms of alpha-catenin function and roles in tumorigenesis. Semin Cancer Biol (2007) 1.76
N-Cadherin expression in human prostate carcinoma cell lines. An epithelial-mesenchymal transformation mediating adhesion withStromal cells. Am J Pathol (1999) 1.70
Alpha-catenin expression has prognostic value in local and locally advanced prostate cancer. Br J Cancer (1999) 1.07
Reduced expression of alpha catenin is associated with poor prognosis in colorectal carcinoma. J Clin Pathol (1999) 0.99
Prognostic significance of E-cadherin-catenin complex in epithelial ovarian cancer. J Clin Pathol (2006) 0.98
Expression of e-cadherin and beta-catenin in human esophageal squamous cell carcinoma: relationships with prognosis. World J Gastroenterol (2003) 0.90
Changes in the expression and subcellular distribution of galectin-3 in clear cell renal cell carcinoma. J Exp Clin Cancer Res (2011) 0.85
Expression of Ksp-cadherin during kidney development and in renal cell carcinoma. Br J Cancer (2005) 0.85
E-Cadherin and beta-Catenin expression in early stage cervical carcinoma: a tissue microarray study of 147 cases. World J Surg Oncol (2005) 0.85
Reduced expression of E-cadherin and p120-catenin and elevated expression of PLC-γ1 and PIKE are associated with aggressiveness of oral squamous cell carcinoma. Int J Clin Exp Pathol (2015) 0.75
Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol (1992) 4.79
DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res (1999) 4.67
Cadherin switching in human prostate cancer progression. Cancer Res (2000) 2.80
Analysis of a cDNA clone expressing a human autoimmune antigen: full-length sequence of the U2 small nuclear RNA-associated B" antigen. Proc Natl Acad Sci U S A (1987) 2.75
Evolutionary conserved close linkage of the c-fes/fps proto-oncogene and genetic sequences encoding a receptor-like protein. EMBO J (1986) 2.73
Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res (1992) 2.55
Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res (1994) 2.34
Allelic loss of chromosomes 16q and 10q in human prostate cancer. Proc Natl Acad Sci U S A (1990) 2.22
Characterization of human c-fes/fps reveals a new transcription unit (fur) in the immediately upstream region of the proto-oncogene. Mol Biol Rep (1986) 2.16
Automated prostate volume determination with ultrasonographic imaging. J Urol (1995) 2.13
Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors. Cancer Res (1993) 2.09
Colocalization of basal and luminal cell-type cytokeratins in human prostate cancer. Cancer Res (1992) 1.98
Cadherin-11 is expressed in invasive breast cancer cell lines. Cancer Res (1999) 1.97
Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int J Cancer (1986) 1.95
Transcriptional regulation of the human E-cadherin gene in human prostate cancer cell lines: characterization of the human E-cadherin gene promoter. Biochem Biophys Res Commun (1994) 1.79
The structure of the human c-fes/fps proto-oncogene. EMBO J (1985) 1.70
A clinical trial with chimeric monoclonal antibody WX-G250 and low dose interleukin-2 pulsing scheme for advanced renal cell carcinoma. J Urol (2006) 1.65
Histological grade heterogeneity in multifocal prostate cancer. Biological and clinical implications. J Pathol (1996) 1.64
fur gene expression as a discriminating marker for small cell and nonsmall cell lung carcinomas. J Clin Invest (1987) 1.63
A practical clinical method for contour determination in ultrasonographic prostate images. Ultrasound Med Biol (1994) 1.60
Selective detrusor activation by electrical sacral nerve root stimulation in spinal cord injury. J Urol (1997) 1.58
Factors affecting recurrence and progression in superficial bladder tumours. Eur J Cancer (1995) 1.58
TNM classification of genitourinary tumours 1987--position of the EORTC Genitourinary Group. Br J Urol (1988) 1.55
Randomized clinical trial on chemoprophylaxis of recurrence in cases of superficial bladder cancer. Cancer Chemother Pharmacol (1983) 1.54
Argyrophilic nucleolar organizer region in proliferating cell has a predictive value for local recurrence in superficial bladder tumor. J Urol (1999) 1.50
Down-regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss. Cancer Res (1996) 1.50
Molecular cloning and characterization of the human E-cadherin cDNA. Mol Biol Rep (1993) 1.45
Preventive effect of a Lactobacillus casei preparation on the recurrence of superficial bladder cancer in a double-blind trial. The BLP Study Group. Eur Urol (1995) 1.45
Prognostic value of cadherin-associated molecules (alpha-, beta-, and gamma-catenins and p120cas) in bladder tumors. Cancer Res (1996) 1.41
Quality-of-life assessment in patients after laser prostatectomy. Br J Urol (1997) 1.41
Evaluation of nucleolar organizer regions in human bladder cancers by light- and electron-microscopic morphometry. Eur Urol (1998) 1.40
Long-term results of donor-specific blood transfusion with cyclosporine in living related kidney transplantation. Nephron (2001) 1.39
Urinary tract infections following laser prostatectomy: is there a need for antibiotic prophylaxis? Br J Urol (1996) 1.38
Prognosis and treatment of T1G3 bladder tumours. A prognostic factor analysis of 121 patients. Dutch South Eastern Bladder Cancer Study Group. Eur J Cancer (1994) 1.38
Comparison of different computer models of the neural control system of the lower urinary tract. Neurourol Urodyn (2000) 1.37
Role of E boxes in the repression of E-cadherin expression. Biochem Biophys Res Commun (1997) 1.37
Differential expression of keratins in the basal and luminal compartments of rat prostatic epithelium during degeneration and regeneration. Prostate (1988) 1.35
Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250. J Clin Oncol (1997) 1.35
Detection of chromosomal imbalances in transitional cell carcinoma of the bladder by comparative genomic hybridization. Am J Pathol (1995) 1.34
The effects of treatment of urinary incontinence in general practice. Fam Pract (1992) 1.32
Increased expression of high mobility group protein I(Y) in high grade prostatic cancer determined by in situ hybridization. Cancer Res (1993) 1.29
Identification of intermediate cell types by keratin expression in the developing human prostate. Prostate (1998) 1.27
Expression of basal cell keratins in human prostate cancer metastases and cell lines. J Pathol (2001) 1.26
Characterization of human prostate cancer, benign prostatic hyperplasia and normal prostate by in vitro 1H and 31P magnetic resonance spectroscopy. J Urol (1993) 1.25
Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250. Int J Cancer (2000) 1.24
Ciprofloxacin distribution in prostatic tissue and fluid following oral administration. Chemotherapy (1985) 1.23
Decreased expression of E-cadherin in the progression of rat prostatic cancer. Cancer Res (1992) 1.23
Metastasectomy in renal cell carcinoma: A multicenter retrospective analysis. Eur Urol (1999) 1.22
Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer: a multicenter Phase II trial in Japan. Jpn J Clin Oncol (2008) 1.22
Controlled trial of pelvic floor exercises in the treatment of urinary stress incontinence in general practice. Br J Gen Pract (1991) 1.22
The correlation between bladder outlet obstruction and lower urinary tract symptoms as measured by the international prostate symptom score. J Urol (1996) 1.19
Molecular analysis of multifocal prostate cancer lesions. J Pathol (1999) 1.19
Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250. Clin Cancer Res (1999) 1.19
Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. J Urol (1993) 1.18
Identification of high mobility group protein I(Y) as potential progression marker for prostate cancer by differential hybridization analysis. Cancer Res (1991) 1.18
Relation between aberrant alpha-catenin expression and loss of E-cadherin function in prostate cancer. Int J Cancer (1997) 1.17
The progression of benign prostatic hyperplasia: examining the evidence and determining the risk. Eur Urol (2001) 1.17
Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer. A flow cytofluorometric analysis. Urol Res (1991) 1.17
Structure and nucleotide sequence of the 5' region of the human and feline c-sis proto-oncogenes. Nucleic Acids Res (1986) 1.16
Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with bacillus Calmette-Guérin. Cancer Immunol Immunother (1991) 1.16
A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients. Br J Cancer (2004) 1.15
Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancer. Cancer Immunol Immunother (1992) 1.15
Incidence of venous thromboembolism following major abdominal surgery: a multi-center, prospective epidemiological study in Japan. J Thromb Haemost (2006) 1.14
High-intensity focused ultrasound (HIFU) followed after one to two weeks by radical retropubic prostatectomy: results of a prospective study. Prostate (1999) 1.13
Complex cadherin expression in human prostate cancer cells. Int J Cancer (2000) 1.13
Predictability of recurrent and progressive disease in individual patients with primary superficial bladder cancer. J Urol (1993) 1.12
Value of the patient's case history in diagnosing urinary incontinence in general practice. Br J Urol (1991) 1.12
Relationship between lower urinary tract abnormalities and disease-related parameters in multiple sclerosis. J Urol (1995) 1.11
Comparative analysis of the human and feline c-sis proto-oncogenes. Identification of 5' human c-sis coding sequences that are not homologous to the transforming gene of simian sarcoma virus. Biochim Biophys Acta (1985) 1.11
Treatment of mid- and lower ureteric calculi: extracorporeal shock-wave lithotripsy vs laser ureteroscopy. A comparison of costs, morbidity and effectiveness. Br J Urol (1998) 1.11
Coordinate recruitment of E-cadherin and ALCAM to cell-cell contacts by alpha-catenin. Biochem Biophys Res Commun (2000) 1.11
A case of intravascular papillary endothelial hyperplasia (Masson's tumor) arising from renal sinus. Jpn J Clin Oncol (1997) 1.10
Better survival in patients with metastasised kidney cancer after nephrectomy: a population-based study in the Netherlands. Eur J Cancer (2011) 1.10
Promoting effects and mechanisms of action of androgen in bladder carcinogenesis in male rats. Eur Urol (1997) 1.09
Posterior tibial nerve stimulation as neuromodulative treatment of lower urinary tract dysfunction. J Urol (2001) 1.08